The numbers are real, the regulatory tailwind is stronger than most exporters realise, and the obstacles are not the ones Indian technology suppliers usually plan for.
For Indian pharmaceutical technology companies, Russia is not a new market. Machinery builders, cleanroom specialists, engineering firms and laboratory suppliers from India have spent two decades installing equipment, supporting expansions and building distributor networks there. The useful question is not whether Russia is worth exporting to. It is whether the market’s current phase rewards a different kind of supplier than the last one did.
On the evidence, it does. But the case is usually made badly, with headline market figures that measure the wrong thing.
Start with production, not consumption
Russia’s pharmaceutical market reached RUB 2.88 trillion in 2025, up 17% on the RUB 2.45 trillion recorded in 2024, according to the annual review published by DSM Group with Ozon Pharmaceuticals in April 2026. The split matters more than the total. Government procurement rose 25.5% to RUB 1.03 trillion, while the pharmacy segment grew 13% to RUB 1.85 trillion. Growth is being led by the state, not the consumer. It is also nominal growth in a high-inflation currency, which is worth remembering before converting it into a business case.
A better number for technology suppliers sits further down the same report. Production of medicines and medical materials rose 15.4% in 2025, against 1.3% growth for Russian industry as a whole. Consumption creates demand for medicines. Output of that order creates demand for the equipment that makes them.
The localisation data points the same way. Domestically produced and localised medicines now account for 69.3% of the market by volume and 46.8% by value, both ahead of the baseline targets set in the Pharma-2030 strategy. In the state hospital segment, Russian-made products account for 87.3% of packs purchased. Note the word localised: it includes foreign brands manufactured inside Russia. AstraZeneca is transferring output of five products to the Skopin plant, and Binnopharm Group is working with China’s Mabwell to localise dupilumab. Every one of those transfers is a line that has to be built, qualified and validated.
Regulation is doing the selling
The strongest argument for the Russian equipment market in 2026 is not commercial. It is regulatory, and it is routinely left out of the pitch.
Since 1 January 2026, Russian manufacturer status has been determined by a points system. A product must score more than 50 points, awarded for carrying out key production stages inside the EAEU. That status is not cosmetic. Under the “second is odd” mechanism, if a single supplier producing a drug through a full cycle within the EAEU, including synthesis of the active ingredient, bids in a state tender, every other bid is rejected. The rule extends fully to strategically significant medicines on 1 July 2026.
Read that from a factory floor. It converts API synthesis, upstream processing and full-cycle capability from a margin question into a condition of market access, in the segment that is growing fastest. Manufacturers who want state business now have a deadline, and deadlines are what generate equipment orders.
Where the capital is landing
The 2025 investment record is specific enough to plan against. Pharm-Sintez is putting RUB 16 billion into a full-cycle antitumour plant in Kaluga region. Nanolek invested RUB 7.5 billion in production for Russia’s first HPV vaccine in Kirov region. Endopharm is investing RUB 5 billion to launch seven high-technology production lines in Moscow. Artcellens has opened the first line of a biotechnology R&D centre in the capital.
Among the larger groups the direction is consistent. Binnopharm Group runs six plants across more than 700,000 square metres and over 20 dosage forms. BIOCAD continues to build biologics capacity. R-Pharm holds offset commitments with the Moscow and St Petersburg city governments worth around RUB 7 billion. Pharmstandard has committed to basic-molecule and haemophilia production. Promomed, a specialty pharma company built around the Biokhimik plant in Saransk, is constructing biotechnology capacity at Alabushevo in the Technopolis Moscow economic zone. Geropharm synthesises insulin substance domestically, which is precisely the full-cycle position the new rules reward.
None of that is a single machine sale. A biologics expansion pulls in cleanrooms, sterile filling, HVAC and laboratory infrastructure. A packaging build pulls in serialisation, inspection and secondary automation. An API plant pulls in reactors, utilities and engineering support. It also pulls in qualification and validation work against EAEU GMP, which is where a supplier with documentation discipline separates itself from one with a good price.
The part the pitch decks leave out
Indian pharmaceutical exports to Russia were USD 577 million in FY2025, according to Indian government figures reported by Reuters in September 2025. The context is worth keeping. That made Russia India’s fifth-largest destination, behind the United States at roughly USD 10.5 billion, the United Kingdom at USD 914 million, Brazil at USD 778 million and the Netherlands at USD 616 million. Reuters reported it as a market India intends to grow, not one it has already won.
Two practical obstacles deserve more attention than they usually get.
The first is compliance scope. Medicines and medical devices sit largely outside Western restrictions under the OFAC General License 6 series. Production machinery does not automatically inherit that carve-out, and industrial and dual-use equipment is where enforcement has concentrated. In October 2024 OFAC designated 19 Indian entities over supplies of technology and dual-use equipment, several of them machinery suppliers. The European Union activated its anti-circumvention instrument for the first time in the twentieth sanctions package, adopted in April 2026. Screening the counterparty and classifying the goods correctly is not paperwork around the deal. It is part of the deal.
The second is payment. There is no direct rupee to rouble rate, some Indian banks decline Russian receipts to protect their Western business, and settlement commonly routes through dirham or yuan. Exporters who structure this at the quotation stage manage it. Those who leave it until the invoice do not.
Why the room still matters
In pharmaceutical manufacturing the tender is the last act, not the first. Technology is chosen during process design and technical evaluation, well before procurement issues an enquiry. By the time the document arrives, the specification usually reflects a supplier who was in the conversation months earlier. For business development teams, responding well to enquiries is therefore a losing strategy dressed up as a diligent one.
That is the case for being in Moscow in November. Pharmtech & Ingredients recorded 534 exhibitors from nine countries and 13,153 visits at its 2025 edition, alongside a conference programme of 20 sessions, 108 speakers and 1,313 delegates. The organisers report that 92% of visitors are involved in purchasing decisions. The 2026 edition runs from 24 to 27 November at Crocus Expo.
The opportunity in Russia is no longer selling more equipment into an installed base. It is being present while manufacturers decide what their next factory looks like.
Sources
Market size, segment split and production growth: DSM Group and Ozon Pharmaceuticals, annual market review, published April 2026.
Localisation shares (69.3% by volume, 46.8% by value, 87.3% of hospital packs) and 2025 investment projects: DSM Group 2025 annual report, as reported by PharmProm, 1 April 2026.
Localisation points system and the “second is odd” mechanism: Russian Federation rules effective 1 January 2026, with full application to strategically significant medicines from 1 July 2026.
Indian pharmaceutical exports by destination, FY2025: Indian government data reported by Reuters, 2 September 2025.
Exhibition figures for the 2025 edition: ITE Group official facts and figures. Visitor purchasing involvement is organiser-reported survey data.
Sanctions and export control references: OFAC General License 6 series; OFAC designations of October 2024; European Union twentieth sanctions package, adopted 23 April 2026.
